
Opinion|Videos|August 14, 2024
Clinical Insights on Next Treatment Approach Steps
A panel of experts in relapsed/refractory multiple myeloma analyzes a patient case, detailing their clinical approach to optimize outcomes for a 68-year-old male presenting with early relapse multiple myeloma.
Advertisement
Video content above is prompted by the following:
- Please describe your initial impressions of this case. How might you have treated this patient in your practice?
Advertisement
Related to this article

The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5

